Novartis AG ADR (NVS)vsOmada Health, Inc. Common Stock (OMDA)
NVS
Novartis AG ADR
$162.55
+0.38%
HEALTHCARE · Cap: $303.67B
OMDA
Omada Health, Inc. Common Stock
$15.09
-20.37%
HEALTHCARE · Cap: $1.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 18419% more annual revenue ($57.36B vs $309.76M). NVS leads profitability with a 17.5% profit margin vs 1.4%. NVS trades at a lower P/E of 30.7x. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
OMDA
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$162.55
$66.99 premium
Intrinsic value data unavailable for OMDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Revenue surging 43.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
1.4% margin — thin
Operating margin of 4.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 43.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : OMDA
The primary concerns for OMDA are EPS Growth, Market Cap, Profit Margin. A P/E of 78.0x leaves little room for execution misses. Thin 1.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a value stock while OMDA is a hypergrowth play — different risk/reward profiles.
OMDA is growing revenue faster at 43.1% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 40/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?